Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alexion Pharm Inc (ALXN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
What's in the Cards for Varian Medical (VAR) in Q1 Earnings?

Varian Medical's (VAR) lackluster performance in Halcyon platform and disappointing financials are likely to dampen results in Q1.

AGIO : 78.35 (+12.10%)
VAR : 110.02 (-0.27%)
ABBV : 106.49 (+1.77%)
ALXN : 123.67 (+2.16%)
What's in the Cards for Biogen (BIIB) This Earnings Season?

On the Q4 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise, and Spinraza's performance.

EBS : 50.41 (-1.52%)
RHHBY : 30.7900 (+0.33%)
ALXN : 123.67 (+2.16%)
BIIB : 347.64 (+1.53%)
Will These 4 Large-Cap Drug Stocks Be Big Winners This Earnings Season?

Here is a look at four large-cap pharma and biotech stocks including Merck (MRK) that could surpass earnings expectations in the fourth quarter.

CELG : 102.91 (+0.25%)
MRK : 61.25 (-0.05%)
ABBV : 106.49 (+1.77%)
JUNO : 86.00 (+26.82%)
SNY : 43.20 (-3.14%)
ALXN : 123.67 (+2.16%)
BIIB : 347.64 (+1.53%)
Alexion to Report Fourth Quarter and Full Year 2017 Results on Thursday, February 8, 2018

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2017 on Thursday, February...

ALXN : 123.67 (+2.16%)
The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex

The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex

CELG : 102.91 (+0.25%)
VRTX : 161.91 (+2.49%)
EXEL : 29.44 (+5.14%)
AMGN : 192.33 (+1.61%)
ALXN : 123.67 (+2.16%)
Azzur New England Introduces New Director of Engineering Services

Azzur Group is pleased to announce that Robert Reddick has joined the company as Director of Engineering Services for the New England office. Rob comes to Azzur from Alexion Pharmaceuticals, where he...

ALXN : 123.67 (+2.16%)
Can Biotech Keep Last Year's Momentum Alive in 2018?

The biotech sector performed impressively in 2017 and the momentum is expected to continue in 2018 driven by new drug approvals. Acquisitions will also remain in focus.

CELG : 102.91 (+0.25%)
VRTX : 161.91 (+2.49%)
EXEL : 29.44 (+5.14%)
GILD : 81.41 (+0.53%)
REGN : 375.86 (+1.17%)
AMGN : 192.33 (+1.61%)
ALXN : 123.67 (+2.16%)
Omeros Inks Agreement With FDA for OMS721 Phase III Trial

Omeros (OMER) inks an agreement with the FDA on Omeros' protocol for a phase III study to evaluate its lead pipeline candidate, OMS721, for treatment of patients with IgA nephropathy.

SCMP : 17.90 (-0.28%)
ACRX : 2.00 (-2.44%)
OMER : 17.18 (+2.87%)
ALXN : 123.67 (+2.16%)
Will These 2 Large-Cap Biotechs Be on Investor Radar in '18?

Both Vertex and Alexion enjoy dominant positions in medical areas - cystic fibrosis (CF) for Vertex and ultra-rare disorders for Alexion - that are not very competitive.

VRTX : 161.91 (+2.49%)
ALXN : 123.67 (+2.16%)
Alexion and Elliott Agree to Collaborate on Identifying a New Board Member

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) said today that its Board of Directors and Elliott have agreed to work collaboratively to promptly identify a new member to join the Alexion Board....

ALXN : 123.67 (+2.16%)
Watch for Alexion Pharm to Potentially Pullback After Gaining 2.77% Yesterday

Alexion Pharm (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $119.99 to a high of $123.90. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of...

ALXN : 123.67 (+2.16%)
Alexion to Present at the 36th Annual J.P. Morgan Healthcare Conference

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 8, 2018 at 9:00...

JPM : 114.33 (+1.17%)
ALXN : 123.67 (+2.16%)
Wired News - Alexion Announced Marketing Authorization of Soliris® in Japan for Treatment of Patients with Generalized Myasthenia Gravis

LONDON, UK / ACCESSWIRE / December 28, 2017 / Active-Investors.com has just released a free research report on Alexion Pharma, Inc. (NASDAQ: ALXN). If you want access to this report all you need to do...

ALXN : 123.67 (+2.16%)
Alexion's (ALXN) Soliris Label Expansion Approved in Japan

Alexion's (ALXN) announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan approved the label expansion of Soliris for the treatment of patients with generalized myasthenia gravis (gMG)....

CORT : 24.70 (+3.00%)
SCMP : 17.90 (-0.28%)
ACHN : 3.01 (+0.67%)
ALXN : 123.67 (+2.16%)
Soliris(R) (Eculizumab) Receives Marketing Authorization in Japan for the Treatment of Patients with Generalized Myasthenia Gravis (gMG)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Soliris(R) (eculizumab) as a treatment for patients...

ALXN : 123.67 (+2.16%)
Alexion to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference

Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that management will present at the Goldman Sachs Healthcare CEOs Unscripted Conference on Thursday, January 4, 2018 at 1:45 p.m....

ALXN : 123.67 (+2.16%)
Achillion's Renal Disease Candidate Gets Orphan Drug Status

Achillion Pharmaceuticals' (ACHN) factor D inhibitor, ACH-4471, gets orphan drug designation for treating C3G, a renal disease.

CORT : 24.70 (+3.00%)
ACHN : 3.01 (+0.67%)
JNJ : 148.14 (+0.53%)
ALXN : 123.67 (+2.16%)
Quotidian Technical Highlights on Selected Biotech Stocks -- Amgen, Alexion Pharma, AnaptysBio, and Akcea Therapeutics

In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on AMGN, ALXN, ANAB, and AKCA which is a click away at http://www.wallstequities.com/registration....

ANAB : 114.78 (-0.12%)
AKCA : 18.53 (+3.52%)
AMGN : 192.33 (+1.61%)
ALXN : 123.67 (+2.16%)
Results of Phase 1b/2 Dose Regimen Optimization Studies for ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Presented at American Society of Hematology (ASH) Meeting

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today the presentation of comprehensive dose-ranging data from two Phase 1b/2 studies of ALXN1210, the Company's investigational long-acting...

ALXN : 123.67 (+2.16%)
Alexion (ALXN) in Focus: Stock Moves 7.2% Higher

Alexion (ALXN) shares rose more than 7% in the last trading session, amid huge volumes.

AKTX : 3.49 (-2.79%)
ALXN : 123.67 (+2.16%)

Van Meerten Stock Picks

My 5 Favorite Mid Cap Stocks
This morning I wanted to find 5 Mid Cap stocks that had great returns over the past year and still seem to have some juice left.
KBH +0.03 , IPGP -2.30 , FSLR -1.07 , NVR -45.00 , SGMS -0.03
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Mar E-mini S&Ps ( ESH18 -0.06% ) this morning are down -0.07% as the partial shutdown of the U.S. government begins for a third day. The Senate has a vote scheduled for 12pm Eastern time to sees if the impasse... Read More

Chart of the Day

Chart of the Day

Catalyst Biosciences (CBIO) is the Barchart Chart of the Day.  The biomedical company has a Trend Spotter buy signal, a Weighted Alpha of 150.22+ and gined 111.86% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures closed the day fractionally on either side of UNCH. The Senate Monday afternoon passed a short terms spending bill, ending the three day government shutdown. This morning's USDA Export Inspections report, not affected by the government s...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.